key: cord-0735382-n0cy7sxx
authors: Yetkin, E.; Yalta, K.; Waltenberger, J.
title: An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation
date: 2020-07-08
journal: Neth Heart J
DOI: 10.1007/s12471-020-01464-4
sha: 20ddc50238a698395b2de690ab7cd93e96c0a071
doc_id: 735382
cord_uid: n0cy7sxx

nan

treatment of COVID-19 patients. In this regard, van den Broek et al. have recently documented that chloroquine significantly prolongs the QT interval in a clinically relevant manner [1] . Chloroquine treatment resulted in a mean QTc prolongation of 35 ms (95% confidence interval (CI) 28-43 ms) using computerised interpretation and 34 ms (95% CI 25-43 ms) using manual interpretation. Although no torsades de pointes were observed during chloroquine treatment, 23% of patients had a QTc interval exceeding 500 ms during chloroquine treatment. These findings highlight the need for ECG monitoring when prescribing chloroquine to COVID-19 patients.

It should be emphasised that the increase in QT interval in COVID-19 patients receiving HCQ has been observed in the absence of concomitant use of azithromycin (AZM). HCQ + AZM could have resulted in a further increase in QT interval in those patients. We would also like to comment on a small but encouraging item in their patient cohort. Given the fact that HCQ is a member of the quina-quina family and has the electrophysiological features of quinidine, it would be valuable to know the details of concurrent antiarrhythmic use (ATC class C01B) in COVID-19 patients in terms of QT prolongation. Van den Broek et al. reported that 4% of patients had already been using antiarrhythmic drugs, ATC class C01B including class Ia, Ib, Ic and class III. Except for the class Ib antiarrhythmic drugs (mexiletine and lidocaine) all ATC class C01B drugs have the potential for QRS and/or QT prolongation. In contrast to class Ia antiarrhythmics and HCQ, class Ib antiarrhythmics have clinically relevant QT-shortening effects [2] . Therefore, it might be a reasonable approach to administer mexiletine and lidocaine in COVID-19 patients with critical QT prolongation or a QT interval exceeding 500 ms. A recent report demonstrated successful completion of HCQ + AZM therapy with shortening of the An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation QR interval from 620 to 550 ms by concurrent use of lidocaine [3] .

In this context, concurrent use of lidocaine and mexiletine might be a promising approach to completing the HCQ and/or AZM treatment in patients with critical QT prolongation or a QT interval exceeding 500 ms.

Conflict of interest E. Yetkin, K. Yalta and J. Waltenberger declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Chloroquine-induced QTc prolongation in COVID-19 patients

Low dose quinidine-mexiletine combination therapy versus quinidine monotherapy for treatment of ventricular arrhythmias

An algorithm for man-agingQTprolongationincoronavirusdisease2019(COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: possible benefits of intravenous lidocaine